These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26690748)

  • 21. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
    Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
    J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 24. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
    Dreicer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
    [No Abstract]   [Full Text] [Related]  

  • 25. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
    von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
    Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
    Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
    Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
    Recine F; Ceresoli GL; Baciarello G; Cerbone L; Calabrò F
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
    Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report.
    McKay RR; Mamlouk K; Montgomery B; Taplin ME
    Clin Genitourin Cancer; 2015 Aug; 13(4):e325-e328. PubMed ID: 25600761
    [No Abstract]   [Full Text] [Related]  

  • 30. The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer.
    Moul JW
    Oncology (Williston Park); 2014 Aug; 28(8):702-3, 722. PubMed ID: 25140628
    [No Abstract]   [Full Text] [Related]  

  • 31. A Case of Locally Advanced Castration-resistant Prostate Cancer With Remarkable Response to Nivolumab.
    Basnet A; Khullar G; Mehta R; Chittoria N
    Clin Genitourin Cancer; 2017 Oct; 15(5):e881-e884. PubMed ID: 28625691
    [No Abstract]   [Full Text] [Related]  

  • 32. Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer.
    Considine B; Petrylak DP
    Oncology (Williston Park); 2019 Mar; 33(3):113-8. PubMed ID: 30866035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Not Available].
    Bernemann C; Bögemann M; Steinestel J; Schrader AJ
    Oncol Res Treat; 2017; 40 Suppl 2():8-10. PubMed ID: 28365708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is it time for everolimus-based combination in castration-resistant prostate cancer?
    Roviello G; Ravelli A; Barni S; Petrelli F; Bottini A; Fox SB; Generali D
    Future Oncol; 2016 Aug; 12(16):1849-52. PubMed ID: 27250597
    [No Abstract]   [Full Text] [Related]  

  • 35. Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?
    Geynisman DM; Plimack ER; Zibelman M
    Eur Urol; 2016 Dec; 70(6):971-973. PubMed ID: 27238654
    [No Abstract]   [Full Text] [Related]  

  • 36. [Antisese oligonucleotide therapy for patients with castration-resistant prostate cancer].
    Muramaki M; Miyake H; Fujisawa M
    Nihon Rinsho; 2016 May; 74 Suppl 3():234-7. PubMed ID: 27344734
    [No Abstract]   [Full Text] [Related]  

  • 37. Editorial Comment to Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
    Sakamoto S
    Int J Urol; 2016 Aug; 23(8):666. PubMed ID: 27325383
    [No Abstract]   [Full Text] [Related]  

  • 38. Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer?
    Fay AP; Bellmunt J
    BJU Int; 2015 Oct; 116(4):500-1. PubMed ID: 26350576
    [No Abstract]   [Full Text] [Related]  

  • 39. PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer.
    Ceci F; Castellucci P; Nanni C; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2103-2104. PubMed ID: 27557847
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA Approves First Treatment for Nonmetastatic, Castration-Resistant Prostate Cancer.
    Aschenbrenner DS
    Am J Nurs; 2018 Jun; 118(6):26. PubMed ID: 29794918
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.